Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome.

摘要

We read with great interest the review by Moscatiello et al. [1] on the importance of targeting all components of the metabolic syndrome (MetS) in the treatment of non-alcoholic fatty liver disease (NAFLD). A few comments may be of interest. One of the hallmarks of MetS is the presence of too many definitions; the joint interim statement of several major organisations published in 2009 [2] attempts to overcome this issue. In this context, the selection of diagnostic criteria may influence the prevalence of MetS [3]. Apart from other cardiovascular risk factors, possible links between NAFLD and elevated serum uric acid (SUA) levels [4] or chronic kidney disease [5] have been recently proposed. Based on this concept, SUA and renal function should be monitored in NAFLD patients.